Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Sedentary Behavior 1Pain 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1Hematologic Neoplasms 1Delirium 1Advanced Cancer 1

Interventions

Standard of Care 6Surveys and Questionnaires 2Interviews as Topic 2zaleplon 1olanzapine-fluoxetine combination 1Videotape Recording 1Rehabilitation 1Referral and Consultation 1Olanzapine 1Neoadjuvant Therapy 1Health Services Needs and Demand 1Fluoxetine 1Decision Support Techniques 1Counseling 1Control Groups 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Advanced Cancer × Olanzapine × Clear all
NCT00512291 2011-09-27

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

M.D. Anderson Cancer Center

Phase NA Completed
25 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡